Explore the Agenda
8:00 am Check-in & Morning Coffee
8:50 am Chair’s Opening Remarks
Supercharging the Asian TPD Ecosystem by Promoting Investment, Partnerships & Licensing Deals to Increase Access to the Global Market
9:00 am Panel Discussion: Navigating Venture Capital Funding & Structuring Strategic Collaborations in South Korea to Accelerate Biotech Growth, Secure Investment & Expand Global Reach
- Understanding Korean venture capital expectations to tailor fundraising strategies, attract competitive capital and enable sustainable biotech scaling
- Identifying how recent deals highlight investor priorities for emerging modalities including novel ligases, non-oncology-targeted degraders, and DACs to guide platform positioning and increase funding success
- Examining how early-stage proof-of-concept studies validate technology, strengthen investor confidence, and accelerate pharma partnership commitments
- Discussing how to structure successful biotech–pharma–academia collaborations in South Korea to balance expectations and maximize the translational speed of your TPD candidate
10:00 am Refreshment Break
10:30 am Networking
This is your opportunity to have face-to-face conversations with fellow attendees of the World Targeted Therapeutics Summit South Korea by Hanson Wade. Progress your TPD candidates forward and make connections with global pharma and biotech working on ADCs, targeted protein degradation, induced proximity, bispecifics, and T-Cell engagers, as well as global service providers, in a mix of pre-organized and ad-hoc networking.
Advancing Degrader Design by Overcoming PK/PD Barriers & Unlocking Novel E3 Ligases to Enable Clinically Viable,
Broadly Applicable TPD Therapeutics
11:30 am Expanding the Landscape of TPD: E3-Agnostic Approach to Unlock the E3 Ligase Space
- Establishing a high‑throughput, phenotype‑driven platform that enables rational E3 ligase selection and uncovers ligases not previously leveraged in TPD to expand degrader design possibilities
- Demonstrating how diverse DOS‑derived chemical scaffolds and ligase deconvolution workflows identify and optimize novel E3 ligase binders for both bifunctional degraders and molecular glue applications
- Leveraging ligases with low bone‑marrow expression to advance safer, orally bioavailable TPD therapeutics with improved selectivity, reduced myelotoxicity, and broad target applicability
12:00 pm Harnessing a Novel E3 Ligase-Targeting DAC to Overcome Hematologic Toxicity in ADCs
- Engineering a degrader payload that recruits a novel E3 ligase to enable selective degradation of tumor-driving proteins with reduced hematologic off-target effects
- Advancing beyond traditional cytotoxic payloads by leveraging targeted protein degradation to minimize collateral damage to healthy blood cell lineages
- Unlocking a new class of safer, next-generation DACs with differentiated biological mechanisms to improve therapeutic index across hematologic indications
12:30 pm Lunch
Advancing DACs, Ubiquitin-Independent & Endocytosis-Free Degradation Modalities to Improve In Vivo Efficacy &
Broaden the Target Landscape for Induced Proximity
1:30 pm Bridging Two Modalities: Explore How Dual-Precision Targeted Protein Degradation (TPD2) Enables Cell-Specific GSPT1 Degradation for Potent Antitumor Activity
- Discover how Orum’s TPD² platform fuses antibody targeting with catalytic protein degradation to deliver potent activity against undruggable intracellular targets
- Discuss ORM-1153, a CD123-targeting Degrader Antibody Conjugate (DAC) with a novel GSPT1-degrading payload, with the aim of achieving selective delivery to AML blasts and inducing cytotoxicity via GSPT1 degradation
- Outline the proprietary linker technology used to enable stable conjugation and subsequent traceless, intracellular release of the TPD payloads from the antibody
2:00 pm Directly Engaging 26S Proteasomes for Ubiquitin-Independent Target Degradation
- Explore how Seoul National university has developed Prote-a-Tac, a targeted protein degradation strategy that directly engages the 26S proteasome, bypassing the need for Ub ligase-mediated polyubiquitination
- Discuss how Prote-a-Tac is a heterobifunctional chimera combining a proteasome-binding module with a target-specific antibody, enabling selective degradation of overexpressed and endogenous proteins
- Outline how the platform is highly modular and specific, allowing flexible target switching and demonstrated high specificity validated by quantitative mass spectrometry
- Discover how the mRNA-based lipid nanoparticle delivery of Prote-a-Tac in cells and mouse xenograft models resulted in effective target degradation and delayed tumor progression
2:30 pm A Novel Platform Technology of Targeted Degradation of Transmembrane Proteins
- Explore how Fudan University has established an endocytosis-independent TPD technology for transmembrane proteins
- Discuss how the technology achieved pM-nM DC50 and >90% Dmax for PD-L1 by small molecule degraders
- Assess how it also achieved significantly better efficacy in vivo than clinical PD-L1 antibodies